Dataset Information

Expanding the clinical use of DBS: through a metabolomic and a lipidomic evaluation

ABSTRACT:

Personalized medicine aims to tailor healthcare to individual characteristics, relying on precise biological data and patient monitoring. Metabolomics and lipidomics play a key role in this approach, providing real-time insights into metabolic states and enabling accurate diagnosis and treatment optimization. However, traditional blood sampling methods are invasive, costly, and logistically complex. Dried Blood Spots (DBS) offer a promising alternative by enabling simple, minimally invasive self-sampling that facilitates remote patient monitoring and enhances clinical research participation. Already used for neonatal screening, DBS are now gaining attention for broader clinical applications, including metabolic and disease monitoring.

This study aimed to optimize pre-analytical conditions for DBS use in metabolomic and lipidomic analyses—evaluating factors such as extraction solvent, punch number, and injection volume—and to compare the biological information obtained from DBS with that from serum. Results demonstrate the potential of DBS as a reliable and practical tool for personalized medicine and clinical research, particularly in decentralized or resource-limited settings.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse-phase, Liquid Chromatography MS - positive - hilic, Liquid Chromatography MS - positive - reverse-phase, Liquid Chromatography MS - alternating - reverse-phase

PROVIDER: MTBLS13382 | MetaboLights | 2026-02-25

REPOSITORIES: MetaboLights

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	a_MTBLS13382_LC-MS_alternating_reverse-phase_metabolite_profiling-1.txt	Txt
	a_MTBLS13382_LC-MS_alternating_reverse-phase_metabolite_profiling-2.txt	Txt
	a_MTBLS13382_LC-MS_alternating_reverse-phase_metabolite_profiling-3.txt	Txt
	a_MTBLS13382_LC-MS_alternating_reverse-phase_metabolite_profiling-4.txt	Txt
	a_MTBLS13382_LC-MS_alternating_reverse-phase_metabolite_profiling.txt	Txt

Items per page:

1 - 5 of 32

Similar Datasets

Project description:Predicting Outcomes of Prostate Cancer Immunotherapyby Personalized Mathematical Models Natalie Kronik1¤, Yuri Kogan1, Moran Elishmereni1, Karin Halevi-Tobias1, Stanimir Vuk-Pavlovic ́2.,Zvia Agur1*.1Institute for Medical BioMathematics, Bene Ataroth, Israel,2College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America Abstract Background:Therapeutic vaccination against disseminated prostate cancer (PCa) is partially effective in some PCa patients.We hypothesized that the efficacy of treatment will be enhanced by individualized vaccination regimens tailored by simplemathematical models.Methodology/Principal Findings:We developed a general mathematical model encompassing the basic interactions of avaccine, immune system and PCa cells, and validated it by the results of a clinical trial testing an allogeneic PCa whole-cellvaccine. For model validation in the absence of any other pertinent marker, we used the clinically measured changes inprostate-specific antigen (PSA) levels as a correlate of tumor burden. Up to 26 PSA levels measured per patient were dividedinto each patient’s training set and his validation set. The training set, used for model personalization, contained thepatient’s initial sequence of PSA levels; the validation set contained his subsequent PSA data points. Personalized modelswere simulated to predict changes in tumor burden and PSA levels and predictions were compared to the validation set.The model accurately predicted PSA levels over the entire measured period in 12 of the 15 vaccination-responsive patients(the coefficient of determination between the predicted and observed PSA values wasR2= 0.972). The model could notaccount for the inconsistent changes in PSA levels in 3 of the 15 responsive patients at the end of treatment. Each validatedpersonalized model was simulated under many hypothetical immunotherapy protocols to suggest alternative vaccinationregimens. Personalized regimens predicted to enhance the effects of therapy differed among the patients.Conclusions/Significance:Using a few initial measurements, we constructed robust patient-specific models of PCaimmunotherapy, which were retrospectively validated by clinical trial results. Our results emphasize the potential value andfeasibility of individualized model-suggested immunotherapy protocols.

Dataset Information

Expanding the clinical use of DBS: through a metabolomic and a lipidomic evaluation

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets